nference

CAMBRIDGE, MA · Biotech · Private

AI agents that integrate and analyze multimodal clinical data to personalize care pathways and accelerate precision research

New patent ·
Claim this profile

Follows are private to you and power your alerts

Updated · nference.com

Sector
Biotech
Headquarters
CAMBRIDGE, MA
Latest Form D
$2.7M, Nov 2022
Total capital
$12.3M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$12.3M
2 Form D · last Nov 2022
48 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
23
17 pending · first 2024
Rank in peer group#1 of 55

Capital timeline

202020212022FEDERAL ↑EQUITY ↓Cumulative $12.3M1st Form D$9.6M2nd Form D$2.7M
202020212022FEDERAL ↑EQUITY ↓Cumulative $12.3M1st Form D$9.6M2nd Form D$2.7M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$2.7M
  • Private capital raisedForm D · SEC · 1st filing$9.6M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 55 peers

Line = median

Biotech · Software

  • Granted patents#1 · top 2%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Murali AravamudanResearcherExecutive Officer, DirectorLinked by 4 patents
  • Agustin MarquezExecutive OfficerNamed in SEC Form D filings
  • Ajit RajasekharanExecutive OfficerNamed in SEC Form D filings
  • Andrew DanielsenDirectorNamed in SEC Form D filings
  • David GoelDirectorNamed in SEC Form D filings
  • Harris FishmanExecutive OfficerNamed in SEC Form D filings
Show all 10 people
  • John HalamkaDirectorNamed in SEC Form D filings
  • Thomas McNaughtonExecutive OfficerNamed in SEC Form D filings
  • Tim BarrowsDirectorNamed in SEC Form D filings
  • Venkataramanan SoundararajanExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 23 granted of 40
Show all 40 patent records
  • Genprex, Inc.Similar federal contract value in Biotech · null in contracts
  • Convelo Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • Octagon Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • HDL THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
  • Encellin, Inc.Similar federal contract value in Biotech · null in contracts
  • MACROGENICS INCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .